Pyxis Oncology (PYXS) Net Income towards Common Stockholders Growth (1y) (2021 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 59.59% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -10.08% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -129.68% |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1,228.66% |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 49.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.06% |
| Sep 30, 2025 | -3.77% |
| Jun 30, 2025 | -4.45% |
| Mar 31, 2025 | -305.63% |
| Dec 31, 2024 | -119.94% |
| Sep 30, 2024 | 10.34% |
| Jun 30, 2024 | -5.08% |
| Mar 31, 2024 | 73.13% |
| Dec 31, 2023 | 55.20% |
| Sep 30, 2023 | 14.55% |
| Jun 30, 2023 | 35.59% |
| Mar 31, 2023 | 36.62% |
| Dec 31, 2022 | -119.87% |
| Sep 30, 2022 | -138.26% |
| Jun 30, 2022 | -330.70% |
| Mar 31, 2022 | 12.16% |
| Dec 31, 2021 | -258.57% |
| Sep 30, 2021 | -263.99% |